Key Developments: Echo Therapeutics Inc (ECTE.PH)
0.22USD
10 May 2013
$-0.57 (-72.15%)
$0.79
$0.22
$0.22
$0.21
2,700
49
$1.59
$0.21
Latest Key Developments (Source: Significant Developments)
Echo Therapeutics Inc Announces Institutional Review Board (IRB) Approval For Clinical Trial Of Symphony CGM System
Echo Therapeutics Inc announced that the Company's clinical trial of Symphony CGM System has received Institutional Review Board (IRB) approval. The IRB approval enables the commencement of a clinical evaluation of Symphony that will support the Company's CE Mark Technical File. Full Article
Echo Therapeutics Inc Announces Closing Of Public Offering Of Common Stock
Echo Therapeutics Inc announced the closing of a previously announced underwritten public offering of 13,633,333 shares of its common stock and the full exercise of the over-allotment option to purchase 2,045,000 additional shares, offered at a price to the public of $0.75 per share. The gross proceeds to Echo from this offering are approximately $11.76 million, before deducting the underwriting discount and other estimated offering expenses payable by Echo. Aegis Capital Corp. acted as the sole book-running manager for the offering. Full Article
Echo Therapeutics Inc Announces Pricing Of Public Offering Of Common Stock
Echo Therapeutics Inc announced the pricing of a previously announced underwritten public offering of 13,333,333 shares of its common stock, offered at a price to the public of $0.75 per share. The gross proceeds to Echo from this offering are expected to be approximately $10.0 million, before deducting the underwriting discount and other estimated offering expenses payable by Echo. Echo Therapeutics has granted the underwriters a 45-day option to purchase up to an aggregate of 2,000,000 additional shares of its common stock to cover over-allotments, if any. The offering is expected to close on or about February 6, 2013. Aegis Capital Corp. is acting as the sole book-running manager for the offering. Full Article
Echo Therapeutics Inc Proposes Public Offering
Echo Therapeutics Inc announced that it intends to offer for sale its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Aegis Capital Corp. is acting as the sole book-running manager for the offering. Full Article
Echo Therapeutics Inc Announces Closing Of Public Offering Of Common Stock
Echo Therapeutics Inc announced the closing of a previously announced underwritten public offering of 3,200,000 shares of its common stock and the fully exercised over-allotment option to purchase 480,000 additional shares, offered at a price of $0.95 per share. The gross proceeds to Echo from this offering were approximately $3.5 million , before deducting the underwriting discount and other offering expenses payable by Echo. Aegis Capital Corp. acted as the sole book-running manager for the offering. Feltl and Company acted as co-manager for the offering. Full Article
Echo Therapeutics Inc Announces Full Exercise Of Over-Allotment Option
Echo Therapeutics Inc announced the full exercise of the over-allotment option granted to the underwriters to purchase 480,000 additional common shares, at a public offering price of $0.95 per share, in connection with its previously announced underwritten public offering of 3,200,000 shares of common stock, bringing the total gross proceeds from the offering to $3,496,000 , before deducting the underwriting discount and other offering expenses payable by Echo. Aegis Capital Corp. acted as the sole book-running manager for the offering. Feltl and Company acted as co-manager for the offering. Full Article
Echo Therapeutics Inc Announces Pricing of Public Offering of Common Stock
Echo Therapeutics Inc announced the pricing of a previously announced underwritten public offering of 3,200,000 shares of its common stock, offered at a price to the public of $0.95 per share. The gross proceeds to Echo from this offering are expected to be approximately $3.0 million, before deducting the underwriting discount and other estimated offering expenses payable by Echo. Echo Therapeutics has granted the underwriters a 45-day option to purchase up to an aggregate of 480,000 additional shares of its common stock to cover over-allotments, if any. The offering is expected to close on or about December 27, 2012. Aegis Capital Corp. is acting as the sole book-running manager for the offering. Feltl and Company is acting as co-manager for the offering. Full Article
Echo Therapeutics Inc Announces Proposed Public Offering
Echo Therapeutics Inc announced that it intends to offer for sale its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Aegis Capital Corp. is acting as the sole book-running manager for the offering. Full Article
Echo Therapeutics Inc Announces Withdrawal Of Proposed Follow-On Offering
Echo Therapeutics Inc announced that it has withdrawn the previously announced proposed underwritten public offering of common stock due to market conditions. Full Article
Echo Therapeutics Inc Announces Proposed Public Offering
Echo Therapeutics Inc announced that it intends to offer for sale its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Aegis Capital Corp. is acting as the sole book-running manager for the offering. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
